What is Immune Therapeutics, Inc. (IMUN) stock price today?

Immune Therapeutics, Inc. (IMUN) is currently trading at $0.09, down 7% today.

What is IMUN P/E ratio?

Immune Therapeutics, Inc.'s P/E ratio is -0.56. This is below the market average, suggesting the stock may be undervalued relative to earnings.

What is IMUN return on equity (ROE)?

Immune Therapeutics, Inc.'s return on equity (ROE) is 67.11%, indicating how efficiently the company generates profit from shareholders' equity. This is considered high quality.

What is Immune Therapeutics, Inc.'s market cap?

Immune Therapeutics, Inc. has a market capitalization of $7.78M.

OTC · Biotechnology

Immune Therapeutics, Inc. (IMUN) Stock

$0.09 -7.00% OTC: IMUN Healthcare

Immune Therapeutics, Inc. currently conducts no significant business operations.

Valuation

Metric	Value
Price	$0.09
Market Cap	$7.78M
P/E Ratio	-0.56
P/B Ratio	0.00
P/S Ratio	0.00
EPS (TTM)	$-0.16
52-Week High	$1.30
52-Week Low	$0.07
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	67.11%
ROA	-600.00%
ROCE	32.80%
Gross Margin	0.00%
Operating Margin	0.00%
Net Margin	0.00%
Debt/Equity	-0.25
Current Ratio	0.01

Annual Financials (USD)

Metric	2018	2019	2020	2021	2022
Revenue	$0	$0	$0	$0	$0
Operating Profit	$-4.0M	$-3.0M	$-1.0M	$-1.0M	$-1.0M
Net Profit	$-8.0M	$-5.0M	$1.0M	$4.0M	$-6.0M
EPS	$-19.03	$-10.44	$2.40	$0.38	$-0.16
Op Margin	-3599.1%	—	—	—	—

Balance Sheet (USD)

Metric	2018	2019	2020	2021	2022
Total Assets	$0	$0	$0	$3.0M	$1.0M
Total Liabilities	$11.0M	$14.0M	$12.0M	$11.0M	$3.0M
Cash	$0	$0	$0	$0	$0
Borrowings	$5.0M	$6.0M	$3.0M	$3.0M	$1.0M

Latest News

Imunon Says Ovarian Cancer Drug Trial Preliminary Results Show Deeper Antitumor Response MT Newswires · Jul 21, 2026 IMUNON Reports Positive Phase 2 MRD Clinical Data for IMNN-001, Demonstrating the Successful Overcoming of Historical IL-12 Safety Barriers in Frontline Ovarian Cancer GlobeNewswire · Jul 21, 2026 Exclusive: Imunon Says Lead Drug Continues To Show Promise in Advanced Ovarian Cancer Patients Benzinga · Jul 21, 2026 OTC Markets Life Sciences Investor Forum: Stacy Lindborg, PhD, President, CEO, and Board Director, of Imunon with Zacks SCR’s David Bautz, PhD Zacks Small Cap Research · Jul 9, 2026 Life Sciences Virtual Investor Forum Presentations Now Available for On-Demand Viewing GlobeNewswire · Jun 26, 2026

Cash Flow (USD)

Metric	2018	2019	2020	2021	2022
Operating Cash Flow	$-1.0M	$0	$0	$0	$-1.0M
Investing Cash Flow	$0	$0	$0	$0	$-1.0M
Financing Cash Flow	$1.0M	$0	$0	$1.0M	$1.0M
Net Cash Flow	$0	$0	$0	$0	$0
Free Cash Flow	$-1.0M	$0	$0	$0	$-1.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	0.00
EV / EBITDA	-0.52
FCF Yield	-5183.92%
Quick Ratio	0.01
Interest Coverage	-8.83
Return 1Y	—
Return 3Y	—
Return 5Y	—

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
BNOEFBionomics Limited	$0.01	-14.89%	-0.30	$8.81M	0.00%
CRBKFCarebook Technologies Inc.	$0.03	+0.00%	-0.15	$6.84M	0.00%
FWPAYForward Pharma A/S	$300.00	-25.09%	2166.67	$7.45M	0.00%
HBCNFHealthBeacon plc	$0.50	+2269.67%	-0.55	$8.44M	0.00%
IPCIFIntellipharmaceutics International Inc.	$0.15	—	-1.72	$4.96M	0.00%

About Immune Therapeutics, Inc.

Immune Therapeutics, Inc. currently conducts no significant business operations. Formerly known as TNI BioTech, Inc., the company adopted its present name in October 2014. Its corporate headquarters are situated in Orlando, Florida.

Immune Therapeutics, Inc. is headquartered in US.

Immune Therapeutics, Inc. (IMUN) stock trades at $0.09 with a market capitalization of $7.78M. The stock is valued at a price-to-earnings (P/E) ratio of -0.56, price-to-book of 0.00, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $0.07 and $1.30, and currently trades 93.1% below its 52-week high.

On profitability, Immune Therapeutics, Inc. generates a return on equity (ROE) of 67.11% — well above the market average, a sign of a high-quality business, return on capital employed of 32.80%, an operating margin of 0.00%, a net profit margin of 0.00%.

Official website: www.immunetherapeutics.com

Related Healthcare Stocks

Screens featuring this stock

High ROE Healthcare Stocks Low P/E Healthcare Stocks High Net Margin Healthcare Stocks Dividend Healthcare Stocks Low Debt Healthcare Stocks All stock screens

Run Stock Screener Investing Guides